In the case of multiple myeloma, mutations are also reported in many other signalling subunits of non-canonical NF-κB pathway—NF-κB2, TRAF2, TRAF3, BTRC encoding β-TrCP, which alters the inhibitory degradative pathway of NIK kinase by TRAF2/TRAF3 complex, leading to malignancy-associated activation of non-canonical NF-κB signalling [150]. The gene discussed is NFKB2; the disease is plasma cell myeloma.